BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C, Huang F, Tang R, Cheng Y, Huang Z, Liang Y, Fan H, Qiao L, Li F, Zhuang W, Peng B, Wang J, Li J, Kuang M. Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH). J Clin Oncol 2023;41:117-27. [PMID: 35921605 DOI: 10.1200/JCO.22.00392] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhong BY, Jin ZC, Chen JJ, Zhu HD, Zhu XL. Role of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma. J Clin Transl Hepatol 2023;11:480-9. [PMID: 36643046 DOI: 10.14218/JCTH.2022.00293] [Reference Citation Analysis]
2 Kawamura Y, Akuta N, Shindoh J, Matsumura M, Okubo S, Tominaga L, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kozuka T, Kumada H. Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinoma. Clin J Gastroenterol 2023;16:1-12. [PMID: 36344851 DOI: 10.1007/s12328-022-01723-4] [Reference Citation Analysis]
3 Ma J, Bo Z, Zhao Z, Yang J, Yang Y, Li H, Yang Y, Wang J, Su Q, Wang J, Chen K, Yu Z, Wang Y, Chen G. Machine Learning to Predict the Response to Lenvatinib Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma. Cancers 2023;15:625. [DOI: 10.3390/cancers15030625] [Reference Citation Analysis]
4 Mawatari S, Tamai T, Kumagai K, Saisyoji A, Muromachi K, Toyodome A, Taniyama O, Sakae H, Ijuin S, Tabu K, Oda K, Hiramine Y, Moriuchi A, Sakurai K, Kanmura S, Ido A. Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma. Cancers (Basel) 2022;14. [PMID: 36551623 DOI: 10.3390/cancers14246139] [Reference Citation Analysis]
5 Li H, Wu Z, Chen J, Su K, Guo L, Xu K, Gu T, Jiang Y, Wang P, Zeng H, Chi H, He K, Han Y. External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Clin Exp Med 2022. [DOI: 10.1007/s10238-022-00972-4] [Reference Citation Analysis]
6 Su C, Teng W, Lin P, Jeng W, Chen K, Hsieh Y, Chen W, Ho M, Hsieh C, Wang C, Chai P, Lin C, Lin C, Lin S. Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma. Cancer Medicine 2022. [DOI: 10.1002/cam4.5506] [Reference Citation Analysis]
7 Huang J, Zhong B, Jiang N, Li W, Zhang S, Yin Y, Yang J, Shen J, Wang W, Zhu X. Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma. JHC 2022;Volume 9:1217-1228. [DOI: 10.2147/jhc.s386672] [Reference Citation Analysis]
8 Wang X, Wu L, Dou Q, Ai L, Lu Y, Deng S, Liu Q, Ji H, Zhang H. Construction of m6A-based prognosis signature and prediction for immune and anti-angiogenic response. Front Mol Biosci 2022;9:1034928. [DOI: 10.3389/fmolb.2022.1034928] [Reference Citation Analysis]
9 Guo P, Pi X, Gao F, Li Q, Li D, Feng W, Cao W. Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study. Front Oncol 2022;12:945915. [DOI: 10.3389/fonc.2022.945915] [Reference Citation Analysis]
10 Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol 2022;28:583-705. [PMID: 36263666 DOI: 10.3350/cmh.2022.0294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
11 Peng W, Zhang X, Li C, Zhu X, Li Q, Chen W, Lu W, Liu C, Zhou Y, Shi Y, Wen T, Sun X. Programmed cell death protein 1 and tyrosine kinase inhibition plus transcatheter arterial chemoembolization of advanced hepatocellular carcinoma. British Journal of Surgery 2022. [DOI: 10.1093/bjs/znac334] [Reference Citation Analysis]
12 Mattingly TJ, Shetty K. The economics of advanced and unresectable hepatocellular carcinoma. Cancer. [DOI: 10.1002/cncr.34456] [Reference Citation Analysis]